GeneDx Holdings P/CF

Mitä GeneDx Holdings tekee? GeneDx Holdings Corp, trading under the ticker WGS, is a health care company headquartered in Stamford, Connecticut. The company went public on September 4, 2020, and currently employs 1,300 people. Its primary focus is delivering health intelligence through genetic diagnostics and data-driven insights. GeneDx offers diagnostic services primarily for pediatric and rare diseases, utilizing whole exome and genome sequencing technologies. The company processes DNA-containing samples through integrated laboratory and informatics systems to analyze genetic variations and provide reports to clinicians and patients. It also provides screening solutions and information services related to genetic diagnostics. The company operates through two segments: GeneDx and Legacy Sema4. The GeneDx segment focuses on pediatric and rare disease diagnostics, while the Legacy Sema4 segment provides reproductive and women’s health diagnostics, as well as somatic oncology testing and screening products. GeneDx Holdings Corp's website is sema4.com, though the company's operations and branding have evolved since its IPO. The company aims to inform diagnosis, guide treatment decisions, and support drug discovery through its genetic data analysis capabilities. GeneDx Holdings on yksi Eurpooliin suosituimmista yhtiöistä.